Thus, these results demonstrate that CARHSP1 promotes the progression of PCa through modulating the expression of IL-17RA and activating its downstream pathway, and suggest that CARHSP1/IL-17RA axis could be a potential novel therapeutic target for PCa. Here, CARHSP1 is linked to posterior cortical atrophy.